Neurosystec Corporation

Valencia, CA 91355

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $953K
First Award Date 04/05/07
Most Recent Award Date 09/01/10

Key Personnel

Last Name Name Awards Contact
Schloss John V. Schloss 1
Lobl Thomas J. Lobl 2

3 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): There is currently no reliable therapy and no cure for tinnitus. Scientists at INSERM in Montpellier, France demonstrated the effectiveness of gacyclidine in an animal model of tinnitus. Later, clinical scientists the Medical University of Hannover (MHH) confirmed that gacyclidine suppressed human tinnitus in...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/18/09 - 08/31/10

DESCRIPTION (provided by applicant): There is currently no reliable therapy and no cure for tinnitus. Scientists at INSERM in Montpellier, France demonstrated the effectiveness of gacyclidine in an animal model of tinnitus. Later, clinical scientists the Medical University of Hannover (MHH) confirmed that gacyclidine suppressed human tinnitus in...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-09
Budget: 04/05/07 - 10/04/07

DESCRIPTION (provided by applicant): There is currently no reliable therapy and no cure for tinnitus. NeuroSystec, in collaboration with basic and clinical scientists at the Kresge Hearing Research Institute (KHRI) and the Medical University of Hannover (MHH), has: 1) confirmed that gacyclidine (NST-001) is effective in animal models for tinnitu...